Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

FDA advisory committee recommends changes in Vioxx and Celebrex labeling

Feb. 22, 2001

Merck reports compounds with the ability to inhibit cytokine production or activity

Feb. 21, 2001

AtheroGenics moves second product into clinical development

Feb. 21, 2001

Review of Aslera NDA rescheduled for April

Feb. 21, 2001

Sankyo presents new cytokine production inhibitors in recent patent

Feb. 20, 2001

Cytokine inhibitors in the Merck pipeline

Feb. 19, 2001

Toleragen candidate for APS reduces disease-causing antibodies, corrects clotting defect in animals

Feb. 16, 2001

Preparation, activity and use of specific IkappaB kinase inhibitors claimed by Aventis

Feb. 15, 2001

Beneficial effects of long-term glucosamine sulfate on osteoarthritis progression

Feb. 14, 2001

KS Biomedix's KSB-301 enters phase II for osteoarthritis

Feb. 12, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...